## Express Mail No.: <u>EV 654 845 568 US</u> Sheet 1 of 3

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
10177-118-999	10/622,293
APPLICANT	
Freyman et al.	
FILING DATE	GROUP
 July 17, 2003	1633

## **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE MM-DD-YY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A55	6,544,168	04/08/03	Alferness	
	A56	6,099,567	08/08/00	Badylak et al.	
	A57	2005/0013872	07/17/03	Freyman	
	A58	7,326,571	02/05/08	Freyman	
	A59	6,962,814	11/08/05	Michell et al.	
	A60	6,082,364	07/04/00	Balian et al.	
	A61	5,762,926	06/09/98	Gage et al.	
	A62	5,650,148	07/22/97	Gage et al.	
	A63	5,632,778	05/27/97	Goldstein	
	A64	5,613,982	03/25/97	Goldstein	
	A65	5,331,972	07/26/94	Wadhwani et al.	
	A66	5,257,632	11/02/93	Turkel et al.	
	A67	5,102,417	04/07/92	Palmaz	
	A68	5,082,670	01/21/92	Gage et al.	
	A69	5,012,818	05/07/91	Joishy	
	A70	4,664,128	05/12/87	Lee	
	A71	4,630,616	12/23/86	Tretinyak	•
,	A72	4,513,754	04/30/85	Lee	
	A73	4,486,188	12/04/84	Altshuler et al.	
<del>-</del>	A74	4,481,946	11/13/84	Altshuler et al.	
	A75	4,314,565	02/09/82	Lee	

			FOREI	GN PATENT DOCUMENTS		
*EXAMINER INITIAL		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE MM-DD-YY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	Т
	B28	WO 01/32129	05/10/01	Gerigene Medical Corporation		
	B29	WO 99/61080	12/02/99	Fidia Advanced Biopolymers S.R.L.		

Sheet 2 of 3 of Replacement 1449 of Application No. 10/622,293

				01/1ppileation 140: 10/022;2/3
B30	WO 99/43270	09/02/99	Gerigene Medical Corporation	
B31	WO 99/30648	06/24/99	The University of Virginia Patent Foundation	
B32	WO 97/18842	05/29/97	Fidia Advanced Biopolymers S.R.L.	
B33	WO 91/18972	12/12/99	Cellco Advanced Bioreactors, Inc.	
B34	WO 90/13332	11/15/90	Cedars-Sinai Medical Center	
B35	WO 01/03750	01/18/01	Advanced Tissue Sciences Inc.	
	B31 B32 B33 B34	B31 WO 99/30648  B32 WO 97/18842  B33 WO 91/18972  B34 WO 90/13332	B31 WO 99/30648 06/24/99  B32 WO 97/18842 05/29/97  B33 WO 91/18972 12/12/99  B34 WO 90/13332 11/15/90	B31       WO 99/30648       06/24/99       The University of Virginia Patent Foundation         B32       WO 97/18842       05/29/97       Fidia Advanced Biopolymers S.R.L.         B33       WO 91/18972       12/12/99       Cellco Advanced Bioreactors, Inc.         B34       WO 90/13332       11/15/90       Cedars-Sinai Medical Center

		NON PATENT LITERATURE DOCUMENTS
*EXAMINER INITIAL		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C53	ANGELE et al., 1999, "Engineering of osteochondral tissue with bone marrow mesenchymal progenitor cells in a derivatized hyaluronan-gelatin composite sponge," Tissue Eng. 5(6):545-554.
	C54	BADYLAK et al., 2001, "Marrow-derived cells populate scaffolds composed of xenogeneic extracellular matrix," Exp Hematol. 29(11):1310-1318.
	C55	BLEIBERG et al., 1987, "New bone formation and bone marrow differentiation induced in rats by extracellular bone matrix implantation: effect of local preirradiation on the process," Exp Hematol. 15(4):309-315.
	C56	DICHEK et al., 1989, "Seeding of intravascular stents with genetically engineered endothelial cells," Circulation 80(5):1347-53.
	C57	HODGES et al., 1996, "Needle aspiration and biopsy in the diagnosis and monitoring of bone marrow diseases," Clin Lab Sci. 9(6):349-353.
	C58	INO et al., 1997, "Dilation mechanism, causes of restenosis and stenting in balloon coarctation angioplasty," Acta Paediatr. 86(4):367-371.
	C59	JIANG et al., 2002, "Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain," Exp Hematol. 30(8):896-904.
	C60	LUPTON et al., 2000, "Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel," Dermatol Surg. 26(2):135-137.
	C61	OLIVER et al., 1976, "Histological studies of subcutaneous and intraperitoneal implants of trypsin-prepared dermal collagen allografts in the rat," Clin Orthop Relat Res. 115:291-302.
	C62	OLIVER et al., 1980, "Effect of aldehyde cross-linking on human dermal collagen implants in the rat," Br J Exp Pathol. 61(5):544-549.
	C63	OLIVER et al., 1981, "Hydroxyproline turnover in dermal collagen grafts in reconstituted skin wounds in the rat," Connect Tissue Res. 9(1):59-62.
	C64	SADOVNIKOVA et al., 1991, "Induction of hematopoietic microenvironment by the extracellular matrix from long-term bone marrow cultures," Ann Hematol. 62(5):160-164.
	C65	SUGITA et al., 1994, "Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation," J Clin Invest. 94(2):481-488.
	C66	VAN DAMME et al., 2002, "Bone marrow stromal cells as targets for gene therapy," Curr Gene Ther. 2(2):195-209.
	C67	VERFAILLIE et al., 2002, "Stem cells: hype and reality," Hematology Am Soc Hematol Educ Program. 369-391.
	C68	International Search Report for International Application No. PCT/US2004/023188.
	C69	BADYLAK, 2004, "Xenogenic extracellular matrix as a scaffold for tissue construction," Transpl Immunol. 12(3-4):367-377.
	C70	BADYLAK, 2007, "The extracellular matrix as a biologic scaffold material," Biomaterials 28(25):3587-3593.
	C71	ROBINSON et al., 2005, "Extracellular matrix scaffold for cardiac repair," Circulation, 112(9 Suppl.):1135-1143.

Sheet 3 of 3 of Replacement 1449 of Application No. 10/622,293

C	72	LEE et al., 1999, "Comparison of bone marrow extracellular matrices," Biochim Biophys Acta. 1428(2-3):300-304.
С		PETERS et al., 1995, "Ovine bone marrow extracellular matrix and soluble protein extraction: fetuin amino terminus microheterogeneity," Am J Med Sci. 309(5):285-294.

EXAMINER DATE CONSIDERED
--------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

